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 Abstract
 Context. MicroRNAs (miRNAs) are short 
noncoding RNAs involved in posttranscriptional regulation 
of gene expression that influence various cellular functions 
including glucose and lipid metabolism and adipocyte 
differentiation. 
 Objective. The aim of this study was to evaluate the 
levels of miR-34a and miR-149 and their relationship with 
metabolic parameters in obese children and adolescents. 
 Design. Seventy children and adolescents were 
enrolled in the study. Plasma levels of microRNAs were 
evaluated by real-time PCR using SYBR green and analyzed 
by ΔCt method. Plasma concentrations of visfatin and insulin 
were measured by ELISA method. Glucose and lipid profile 
were determined colorimetrically. HOMA-IR was calculated 
and used as an index of insulin resistance (IR). 
 Results. miR-34a was significantly lower in 
subjects with insulin resistance compared to obese children 
with normal insulin sensitivity. There was an inverse 
relationship between miR-34a levels and both insulin and 
HOMA-IR. On the other hand, miR-149 was significantly 
correlated with visfatin. There was no significant difference 
in miR-34a and miR-149 between obese and normal weight 
subjects. 
 Conclusions. miR-34a is associated with insulin 
and HOMA-IR and thus seems to be involved in IR. miR-
149 is inversely associated with visfatin levels which could 
be indicative of anti-inflammatory effect of this miRNA.
 Key words: obesity, miR-34a, miR-149, insulin 
resistance.
INTRODUCTION
 The World Health Organization (WHO) has 
reported obesity as the global pandemic of the 21st 
century (1). Childhood obesity participates in metabolic 
abnormalities which lead to disorders such as insulin 
resistance, type 2 diabetes, metabolic syndrome (MetS) 
and cardiovascular disease (2). Obesity is accompanied 
by increased adipose tissue mass. Adipose tissue is not 
only a storage tissue for lipids but also it functions as 
an endocrine organ and releases various adipokines 
such as visfatin that influence other tissues and cause 
changes in gene expression patterns and metabolic 
homeostasis throughout the body (3). Visfatin, also 
known as pre-B-cell colony-enhancing factor (PBEF) 
or nicotinamide phosphoribosyl transferase (NAMPT), 
has been shown to be implicated in obesity and its long-
term consequences including insulin resistance. Altered 
visfatin levels have been reported in obesity, diabetes 
mellitus, cardiovascular disorders, kidney diseases and 
bone disorders and different types of cancers (4, 5). 
 MicroRNAs (miRNAs) are endogenous ~23-
nt RNA molecules that regulate gene expression 
by pairing to the 3’- untranslated region (UTR) of 
target mRNAs of protein-coding genes to direct their 
post transcriptional suppression (6). MicroRNAs 
play key roles in controlling metabolic homeostasis 
and regulation of insulin signaling and therefore are 
involved in inflammation, dyslipidemia and insulin 
resistance. Hundreds of miRNAs are actively or 
passively released into the circulation and can be used 
to assess health condition and disease development (7). 
The expression of miRNAs is influenced by obesity 
and may be effective in promoting obesity-associated 
metabolic abnormalities such as insulin resistance and 
type 2 diabetes. 
 MicroRNA-34a (miR-34a) is a part of the p53 
tumor suppressor network (8). The mature miR-34a is 
one of the major miRNAs involved in insulin production, 
pancreatic development and glucose homeostasis 
(9). A number of studies have shown that elevated 
miR-34a decreases NAD+ levels by directly targeting 
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nicotinamide phosphoribosyltransferase (NAMPT) (4, 
5). NAMPT, which is secreted from adipose tissue as an 
adipokine called visfatin, has been shown to be elevated 
in obesity (10). MiR-34a levels are highly elevated in 
the fatty livers of both diet-induced obese mice and the 
leptin-deficient ob/ob mice (11, 12). Circulating levels 
of miR-34a correlate with hepatic disease severity in 
patients with chronic hepatitis C infection (CHC) or 
non-alcoholic fatty-liver disease (NAFLD) and diabetes 
mellitus (13, 14). 
 The aim of this study was to investigate the 
association of plasma levels of miR-34a and miR-149 




 Seventy children between the ages of 8-16 years 
old (35 obese and 35 normal subjects) were enrolled in 
this cross-sectional study. After a routine medical history 
acquisition and health examination, the subsequent 
factors were assessed: waist circumference (WC), hip 
circumference (HC), waist to hip ratio (WHR), weight, 
height, systolic (SBP) and diastolic (DBP) blood pressure. 
Body mass index (BMI) was calculated using the 
formula weight [kg]/ (height)2 [m2] and BMI z-score and 
percentiles were determined according to sex and age of 
each subject. WC-SD (standard deviation), SBP-SD and 
DBP-SD values were calculated by the Anthropometric 
Calculator for normal children 0-20 years of age 
developed by the Canadian Pediatric Endocrine Group 
based on NHLBI 2004 guidelines (15) and US Centers 
for Disease Control and Prevention (CDC) 2000 growth 
charts, according to the age and gender of each subject 
(16). BMI percentiles were also determined according to 
the sex-specific 2000 growth charts of CDC (17). Those 
with BMI ≥ 95th percentile were considered to be obese 
and those with BMI between 5th and 85th percentile were 
enrolled as the control group. None of the subjects had 
current illness and any history of disease. Those who 
were taking medications were excluded from the study. 
 The homeostatic model assessment of insulin 
resistance HOMA-IR was used to evaluate IR and was 
determined with the formula (fasting insulin [μIU/
mL] × fasting glucose [mg/dL])/405 (18). Those with 
HOMA-IR-values greater than 3.16 were classified as 
having IR (19). 
 MetS was diagnosed based on the presence of 
abdominal obesity (WC above 90th percentile for age 
and sex) (20), and two or more other clinical features 
including elevated glucose, TG, SBP or DBP, or low 
HDL-C, according to the IDF consensus definition of 
MetS in children and adolescents (21). 
 Written informed consent was obtained from 
subjects and/or their parents. This study was approved 
by the Ethics Committee of Iran University of Medical 
Sciences.
 Sample collection and biochemical 
measurements
 Venous blood samples were drawn after 
an overnight fast. Plasma samples were prepared in 
RNase-free tubes at 4oC and kept frozen at -80oC for 
microRNA extraction. Serum samples were used for 
other biochemical measurements. 
 Fasting plasma glucose (FPG), triglyceride 
(TG), total cholesterol (TC), high density lipoprotein 
cholesterol (HDL-C) and low density lipoprotein 
cholesterol (LDL-C) were measured by enzymatic 
methods using calorimetric kits (Parsazmoon, 
Iran). Insulin was measured using Enzyme-Linked 
Immunosorbent Assay (ELISA) kit (Monobind, USA). 
In order to measure visfatin, plasma samples were 
separated immediately at 4oC. Visfatin was measured 
by an ELISA kit (AdipoGen, Switzerland). 
 MicroRNA Isolation and cDNA synthesis
 The RNA fraction isolated from plasma 
contains small RNA species less than 100 nucleotides. 
The total RNA was extracted from 200 μL of plasma 
sample using the miRNeasy serum/plasma Kit 
(QIAGEN GmbH, Hilden, Germany) that uses phenol/
guanidine-based lysis of samples and silica membrane–
based purification of total RNA. QIAzol Lysis Reagent 
was used to inhibit RNase and also to eliminate most 
of the cellular DNA and proteins from the lysate by 
organic extraction. Similar amounts of miRNeasy 
Serum/Plasma Spike-In Control (1.6 x108 copies/
μL) were added to each sample prior to extraction to 
monitor the extraction efficiency. 
 Poly(A) Polymerase was used to add a poly (A) 
tail and elongate miRNAs. Reverse transcriptase from 
RevertAid first strand cDNA synthesis kit (Thermo 
Scientific, USA) was used for the synthesis of cDNA 
with a primer containing complementary sequence for 
the poly (A) tail and an adapter sequence (Table 1).  
 Real-time PCR
 Real-time qPCR was performed for the 
measurement of miRNA levels using SYBR green 
(TaKaRa, Shiga, Japan) using both miRNA-specific 
miR-34a and miR-149 in childhood obesity
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and universal primers. PCR program contained an 
initial denaturation at 95¯C for 15 s, followed by 40 
cycles of 95¯C for 3 s and 60¯C for 30 s with the Rotor-
Gene 6000™ (Corbett Research). The sequences of 
primers are shown in Table 1. 
 Normalization of the miRNA levels was 
carried out by assessing miR-16 expression. A primer 
for Cel-miR-39-1 (miScript Primer Assay, Qiagen, 
USA) was used for measuring the previously added 
Spike-In control to ensure reproducibility. A standard 
curve containing 103 - 106 copies of Cel-miR-39 cDNA 
was generated independent of a serum/plasma sample 
and RNA purification procedure, allowing estimation 
of the recovery of miRNeasy Serum/Plasma Spike-In 
Control. 
 A melt curve was also generated after each 
reaction. Relative expressions of miRNA levels were 
determined by ΔCt using the equation Ct normalizer - 
Ct specific miRNA. 
 Statistical analysis
 Analysis of the results was performed by 
Mann-Whitney test for non-parametric variables and 
independent samples t-test for parametric variables 
and the chi-square (for gender distribution) using 
SPSS software version 16.0 (SPSS, Inc., Chicago, 
IL, USA). Normal distribution of data was evaluated 
by Kolmogorov–Smirnov test. Association between 
different parameters was analyzed by Pearson’s and 
Spearman’s correlation analysis for parametric and 
non-parametric variables, respectively. P values below 
0.05 were considered to be significant. 
RESULTS
 The baseline experimental features and 
demographic variables of the study groups are 
presented in Table 2. There were no statistically 
significant differences in age and gender distribution of 
the case and control groups. Both HC and WC and their 






Adaptor 5’- GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTAG -3’
Table 1. Sequences of primers
 Characteristics Control group Obese group P value
Female/male 20 /15 22/13 n.s.
Age (years) 11.42 ± 2.18 10.95 ± 2.73 n.s.
BMI (kg/m2) 18.41 ± 2.64 28.12 ± 5.7 < 0.001
BMI z-score 0.683 ± 0.91 2.09 ± 0.45 < 0.001
WC (cm) 61.65 ± 6.57 84.80 ± 13.45 < 0.001
WC-SD -0.44 ± 0.8 1.55 ± 0.4 < 0.001
HC (cm) 78.37 ± 8.1 97.62 ± 13.62 < 0.001
WHR 0.78 ± 0.47 0.87 ± 0.89 < 0.001
SBP (mmHg) 95.43 ± 11.96 101.14 ± 14.50 < 0.001
SPB-SD -0.69 ± 1.1 -0.33 ± 1.3 n.s.
DBP (mmHg) 68.57 ± 8.7 72.57 ± 12.21 < 0.001
DBP-SD 0.73 ± 0.7 0.71 ± 1.3 n.s.
FPG (mg/dL) 90.0 ± 4.92 92.05 ± 6.54 < 0.001
TG (mg/dL) 73.94 ± 31.93 126.6 ± 69.0 0.001
TC (mg/dL) 148.65 ± 19.06 171.54 ± 24.97 0.001
LDL-C (mg/dL) 75.80 ± 13.14 92.48 ± 16.81 0.024
HDL-C (mg/dL) 54.60 ± 7.50 47.65 ± 9.5 0.036
Insulin (μIU/dL) 7.74 ± 10.13 19.77 ± 9.64 < 0.001
HOMA-IR 1.75 ± 2.40 4.50 ± 2.22 < 0.001
Visfatin (ng/mL) 1.49 ± 0.87 2.08 ± 1.033 < 0.001
Table 2. The baseline experimental characteristics and demographic variables
Values are expressed as mean ± SD. BMI: body mass index; WC, waist circumference; WC-SD, waist circumference standard deviation; WHR, waist-to-hip 
ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; LDL-C, low-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance. 
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obese subjects compared to normal subjects. SBP and 
DBP were also significantly higher in obese subjects. 
However, no significant difference was observed for 
SBP-SD and DBP-SD between obese and normal 
subjects. 
 Significant differences were observed in lipid 
profile between cases and controls. All of the indices of 
glycemic control including FPG, insulin and HOMA-
IR were higher in obese subjects. Visfatin levels were 
also significantly elevated in the obese group compared 
with the control group.
 Among obese subjects 31% were diagnosed 
as having MetS and 74% were found to be insulin 
resistant. 
 Semi-quantitative real-time PCR was used 
for the evaluation of plasma miR-34a and miR-149 
expressions in both groups. Analysis by Δct method 
showed that there were no significant differences in the 
levels of miR-34a and miR-149 in control and obese 
groups.
 There was also no statistically significant 
differences in the levels of these microRNAs in obese 
subjects with or without MetS. Plasma levels of miR-
34a were found to be significantly reduced (P=0.001) 
in subjects with IR compared to the control group 
(Fig. 1). However, there was no statistically significant 
difference in the level of miR-149 in these two groups. 
 The correlation analysis showed that the 
plasma miR-149 level was negatively correlated with 
the serum visfatin level (r = -0.302, p = 0.001).
 On the other hand, serum miR-34a level was 
negatively correlated with insulin (r=-0.285, p=0.022) 
and HOMA-IR (r=-0.281, p=0.023) (Figures 2A and 
2B). No association was found between miR-149 and 
the other variables.
DISCUSSION
 Childhood obesity causes a wide range of 
severe problems and augments the risk of premature 
disease. In obesity, elevation of inflammatory factors 
such as visfatin may lead to IR, impaired glucose 
tolerance and consequently type 2 diabetes (22).  
 Some miRNAs are related to adipocytokines 
and insulin function. Recently, researchers have 
focused on the link between miRNAs and disorders 
such as obesity and diabetes. In the present study, 
we showed that the plasma miR-34a had significant 
Figure 1. Real-time quantitative RT-PCR analysis of plasma miR-34a 
in groups with and without insulin resistance. miR-34a levels were 
calculated after normalizing with miR-16. P<0.001 compared to 
subjects without insulin resistance.
Figure 2. (A) The negative correlation between miR-34a levels and insulin (r=-0.450, p=0.001). (B) The negative correlation between miR-34a 
levels and HOMA-IR (r=-0.447, p=0.002). 
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negative correlations with insulin and HOMA-IR. No 
association was found between miR-34a, miR-149 and 
the other related variables. Also, there was no significant 
difference in the levels of miR-34a and miR-149 in 
obese and control groups, but miR-34a expression was 
significantly lower in those with IR compared to the 
obese subjects with normal insulin sensitivity.
 MicroRNA-34a has various roles in insulin 
secretion, p53-dependent apoptosis, regulation of 
sirtuins 1 expression, hepatic lipid homeostasis, cancer 
and cardiovascular disease (23). Previous studies have 
shown that miR-34a is overexpressed in non-alcoholic 
steatohepatitis (NASH) in mice (13). Some studies 
have also reported significantly increased miR-34a in 
patients with non-alcoholic fatty liver disease (NAFLD)
(24) which may be related to the tissue damage induced 
by lipid disorders, because there is a link between liver 
cell apoptosis, miR-34a and NAFLD severity (25). 
 The most prominent finding of the current study 
is the association of miR-34a with insulin resistance in 
obese children. MicroRNA-34a has been previously 
found to be associated with diabetes. The expression 
of miR-34a is augmented in the islets of non-obese 
diabetic mice during development of pre-diabetic IR 
(26). On the other hand, increased miR-34a expression 
leads to sensitization of β cells to apoptosis and 
destruction in nutrient-induced insulin secretion (27). 
MicroRNA-34a decreases the expression of VAMP2, a 
sensitive factor attachment protein receptor (SNARE) 
that is essential for insulin exocytosis (28). Therefore, 
decreased miR-34a levels may lead to increased insulin 
secretion which is consistent with our findings. 
 Although visfatin is a direct target of miR-34a 
and reduction of visfatin activity by miR-34a has been 
reported (29), we did not find a significant correlation 
between these two parameters which may be the result 
of interaction of several other factors and shows that in 
vitro relationships between miRNAs and their targets 
are not necessarily reflected in the blood circulation. 
On the other hand, miR-149 showed a significant 
negative correlation with visfatin. MicroRNA-149 
inhibits poly (ADP-ribose) polymerase-2 (PARP-2) 
and subsequently increases cellular NAD+ levels and 
SIRT-1 activity (30) suggesting a relationship between 
miR-149 and visfatin. It has also been reported that 
miR‐149 inhibits inflammatory cytokines, tumor 
necrosis factor-α (TNF‐α) and IL-6 (31) which 
increase the production of visfatin (32). Thus miR-
149 may indirectly reduce visfatin, exerting an anti-
inflammatory function.
 Other miRNAs, such as miR-494 are also 
involved in reducing insulin secretion which may be 
attributable to resistin, and contribute to pathogenesis 
of diabetes (33).
 In conclusion, according to the results of the 
present study, the plasma miR-34a is correlated with 
insulin and HOMA-IR, suggesting a role for miR-
34a in the pathogenesis of diabetes and its potential 
as an early biomarker for identification of insulin 
resistance. Further studies are needed to clarify the link 
of miR-149, miR-34a and obesity-associated metabolic 
abnormalities. 
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